Mission Bay Capital is a venture capital firm for early-stage investments.
Business Model:
Revenue: $12.7M
Employees: 2-10
Address: 1700 4th St
City: San Francisco
State: CA
Zip: 94143
Country: US
Mission Bay Capital is a venture capital firm specializing in seed and early-stage investments.
Contact Phone:
+14152404970
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2018 | GraphWear Technologies | Series A | 0 |
6/2017 | Vivace Therapeutics | Series B | 25M |
3/2018 | ViewPoint Therapeutics | Series B | 0 |
11/2015 | Atreca | Series A | 56M |
9/2016 | Tangible Science | Venture Round | 3M |
4/2020 | Nitrase Therapeutics | Series A | 38M |
8/2019 | Glycomine | Series B | 0 |
9/2016 | Chrono Therapeutics | Series B | 47.6M |
10/2012 | Principia Biopharma | Series A | 12.5M |
1/2016 | Alector | Series D | 29.5M |
7/2010 | Calithera Biosciences | Series A | 40M |
3/2018 | Wildtype | Seed Round | 0 |
3/2023 | QurAlis | Series B | 0 |
12/2016 | Circle Pharma | Series A | 0 |
12/2015 | Effector Therapeutics | Series B | 40M |
12/2017 | Pionyr Immunotherapeutics | Series B | 0 |
7/2021 | Nobell Foods | Series B | 75M |
11/2014 | Bolt Threads | Series A | 0 |
6/2015 | Bolt Threads | Series B | 0 |
3/2015 | Caribou Biosciences | Series A | 0 |
9/2015 | Alector | Series C | 32M |
4/2017 | LogicInk | Pre Seed Round | 1M |
12/2017 | Sound Agriculture | Series B | 12.3M |
6/2016 | Cell Design Labs | Equity | 34.4M |
4/2010 | Redwood Bioscience | Seed Round | 300k |
4/2012 | Magnamosis | Seed Round | - |
5/2016 | Caribou Biosciences | Series B | 30M |
3/2015 | Tangible Science | Angel Round | 1M |
5/2016 | ViewPoint Therapeutics | Series A | 0 |
9/2014 | Zephyrus Biosciences | Seed Round | 1.5M |
9/2014 | Circle Pharma | Seed Round | - |
7/2018 | Alector | Series E | 133M |
9/2020 | Symbiome | Venture Round | 0 |
11/2021 | Nitrase Therapeutics | Series A | 0 |
1/2017 | SiteOne Therapeutics | Series B | 0 |
6/2013 | Tangible Science | Seed Round | 600k |
7/2015 | SiteOne Therapeutics | Venture Round | 0 |
4/2014 | Principia Biopharma | Series B | 50M |
1/2017 | Pionyr Immunotherapeutics | Series A | 8M |
5/2013 | Effector Therapeutics | Series A | 45M |
11/2021 | Nitrase Therapeutics | Series A | 0 |
7/2021 | Nobell Foods | Series B | 0 |
9/2020 | Symbiome | Venture Round | 0 |
4/2020 | Nitrase Therapeutics | Series A | 0 |
8/2019 | Glycomine | Series B | 0 |
7/2018 | Alector | Series E | 0 |
4/2018 | GraphWear Technologies | Series A | 0 |
3/2018 | Wildtype | Seed Round | 0 |
3/2018 | ViewPoint Therapeutics | Series B | 0 |
12/2017 | Pionyr Immunotherapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|